[Form 3] TAKEDA PHARMACEUTICAL CO LTD Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Takeda Pharmaceutical director Emiko Higashi filed an initial ownership report showing equity and award holdings in the company. The filing lists 7,600 American Depositary Shares and 17,800 Ordinary Shares held directly, plus restricted stock units and tax-related awards tied to future vesting.

Footnotes explain that 12,800 restricted stock units each convert into one Ordinary Share, then into American Depositary Shares, vesting on June 1, 2026, 2027, 2028 and upon conclusion of board service. Separate Tax Obligation Awards are each economically equivalent to one Ordinary Share and will be settled in cash at vest primarily to cover tax obligations.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Higashi Emiko

(Last) (First) (Middle)

C/O KLA CORPORATION

ONE TECHNOLOGY DRIVE

(Street)

MILPITAS CALIFORNIA 95035

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	7,600	D
Ordinary Shares	17,800(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Tax Obligation Award	06/01/2026	06/01/2026	Ordinary Shares	1,152	(2)	D
Tax Obligation Award	06/01/2027	06/01/2027	Ordinary Shares	1,192	(2)	D
Tax Obligation Award	06/01/2028	06/01/2028	Ordinary Shares	1,180	(2)	D
Tax Obligation Award	(3)	(3)	Ordinary Shares	3,432	(2)	D

Explanation of Responses:

1. Includes 12,800 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on the following schedule: June 1, 2026 (3,100 shares), June 1, 2027 (3,400 shares), June 1, 2028 (3,200 shares) and upon conclusion of the director's board service (3,100 shares).

2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.

3. Vests upon conclusion of the director's service on the board.

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Emiko Higashi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)